<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20241120215120&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20241120215120&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 21 Nov 2024 02:51:21 +0000</lastbuilddate>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiovascular magnetic resonance imaging in mitral valve disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>This paper describes the role of cardiovascular magnetic resonance (CMR) imaging in assessing patients with mitral valve disease. Mitral regurgitation (MR) is one of the most prevalent valvular heart diseases. It often progresses without significant symptoms, leading to left ventricular overload, dysfunction, frequent decompensated heart failure episodes, and excess mortality. Cardiovascular magnetic resonance assessment is recommended for MR when routine ultrasound imaging information is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae801. doi: 10.1093/eurheartj/ehae801. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This paper describes the role of cardiovascular magnetic resonance (CMR) imaging in assessing patients with mitral valve disease. Mitral regurgitation (MR) is one of the most prevalent valvular heart diseases. It often progresses without significant symptoms, leading to left ventricular overload, dysfunction, frequent decompensated heart failure episodes, and excess mortality. Cardiovascular magnetic resonance assessment is recommended for MR when routine ultrasound imaging information is insufficient or discordant. A well-planned CMR can provide an in-depth assessment of the mitral valve apparatus, leaflet morphology, and papillary muscles. In addition, it can precisely inform the impact of MR on left atrial and ventricular remodelling. The review aims to highlight established and emerging techniques for morphological assessment, flow assessment (including regurgitation and stenosis), myocardial assessment, and haemodynamic assessment of mitral valve disease by CMR. It also proposes a simplified clinical flow chart for CMR assessment of the mitral valve.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565911</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae801>10.1093/eurheartj/ehae801</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565911</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Pankaj Garg</dc:creator>
<dc:creator>Anna Giulia Pavon</dc:creator>
<dc:creator>Martin Penicka</dc:creator>
<dc:creator>Seth Uretsky</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular magnetic resonance imaging in mitral valve disease</dc:title>
<dc:identifier>pmid:39565911</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae801</dc:identifier>
</item>
<item>
<title>Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this systematic review and individual patient data meta-analysis suggest that compared with a high-intensity statin strategy, the alternative LDL cholesterol-lowering strategy demonstrated comparable efficacy regarding 3-year death or cardiovascular events in patients with ASCVD, with an associated reduction in LDL cholesterol levels and risk for new-onset diabetes and intolerance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 20. doi: 10.1001/jamacardio.2024.3911. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In patients with atherosclerotic cardiovascular disease (ASCVD), intensive lowering of low-density lipoprotein (LDL) cholesterol levels with high-intensity statins is generally recommended. However, alternative approaches considering statin-related adverse effects and intolerance are needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare the long-term efficacy and safety of an alternative LDL cholesterol-lowering strategy vs high-intensity statin strategy in patients with ASCVD in randomized clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: PubMed, Embase, and other websites (ClinicalTrials.gov, European Society of Cardiology, tctMD) were systematically searched from inception to April 19, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Randomized clinical trials comparing an alternative LDL cholesterol-lowering strategy vs a high-intensity statin strategy in patients with ASCVD, with presence of cardiovascular events as end points.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: Individual patient data were obtained from randomized clinical trials that met the prespecified eligibility criteria: RACING (Randomized Comparison of Efficacy and Safety of Lipid-Lowering With Statin Monotherapy vs Statin/Ezetimibe Combination for High-Risk Cardiovascular Disease) and LODESTAR (Low-Density Lipoprotein Cholesterol-Targeting Statin Therapy vs Intensity-Based Statin Therapy in Patients With Coronary Artery Disease). The moderate-intensity statin with ezetimibe combination therapy in the RACING trial and the treat-to-target strategy in the LODESTAR trial were classified as alternative LDL cholesterol-lowering strategies. The primary analysis was based on a 1-stage approach.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was a 3-year composite of all-cause death, myocardial infarction, stroke, or coronary revascularization. The secondary end points comprised clinical efficacy and safety end points.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Individual patient data from 2 trials including 8180 patients with ASCVD (mean [SD] age, 64.5 [9.8] years; 2182 [26.7%] female; 5998 male [73.3%]) were analyzed. The rate of the primary end point did not differ between the alternative strategy and high-intensity statin strategy groups (7.5% [304 of 4094] vs 7.7% [310 of 4086]; hazard ratio, 0.98; 95% CI, 0.84-1.15; P = .82). The mean (SD) LDL cholesterol level during treatment was 64.8 (19.0) mg/dL in the alternative strategy group and 68.5 (20.7) mg/dL in the high-intensity statin strategy group (P &lt; .001). The alternative strategy group had a lower rate of new-onset diabetes (10.2% [271 of 2658] vs 11.9% [316 of 2656]; P = .047), initiation of antidiabetic medication for new-onset diabetes (6.5% [173 of 2658] vs 8.2% [217 of 2656]; P = .02), and intolerance-related discontinuation or dose reduction of assigned therapy (4.0% [163 of 4094] vs 6.7% [273 of 4086]; P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this systematic review and individual patient data meta-analysis suggest that compared with a high-intensity statin strategy, the alternative LDL cholesterol-lowering strategy demonstrated comparable efficacy regarding 3-year death or cardiovascular events in patients with ASCVD, with an associated reduction in LDL cholesterol levels and risk for new-onset diabetes and intolerance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY REGISTRATION: PROSPERO CRD42024532550.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565634</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3911>10.1001/jamacardio.2024.3911</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565634</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yong-Joon Lee</dc:creator>
<dc:creator>Bum-Kee Hong</dc:creator>
<dc:creator>Kyeong Ho Yun</dc:creator>
<dc:creator>Woong Chol Kang</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Sang-Hyup Lee</dc:creator>
<dc:creator>Seung-Jun Lee</dc:creator>
<dc:creator>Sung-Jin Hong</dc:creator>
<dc:creator>Chul-Min Ahn</dc:creator>
<dc:creator>Jung-Sun Kim</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:creator>Donghoon Choi</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis</dc:title>
<dc:identifier>pmid:39565634</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3911</dc:identifier>
</item>
<item>
<title>Palpitations After Transcatheter Atrial Septal Defect Closure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 20. doi: 10.1001/jamacardio.2024.4124. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565632</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4124>10.1001/jamacardio.2024.4124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565632</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Goran Medimurec</dc:creator>
<dc:creator>Željko Ðuric</dc:creator>
<dc:creator>Irena Ivanac Vranešic</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Palpitations After Transcatheter Atrial Septal Defect Closure</dc:title>
<dc:identifier>pmid:39565632</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4124</dc:identifier>
</item>
<item>
<title>Xylitol exposure and cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae730. doi: 10.1093/eurheartj/ehae730. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565331</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae730>10.1093/eurheartj/ehae730</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565331</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Bettina K Wölnerhanssen</dc:creator>
<dc:creator>Anne Christin Meyer-Gerspach</dc:creator>
<dc:creator>Arduino Arduini</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Xylitol exposure and cardiovascular risk</dc:title>
<dc:identifier>pmid:39565331</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae730</dc:identifier>
</item>
<item>
<title>Gold standard: Karin Sipido honoured for pioneering work</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae741. doi: 10.1093/eurheartj/ehae741. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565328</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae741>10.1093/eurheartj/ehae741</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565328</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gold standard: Karin Sipido honoured for pioneering work</dc:title>
<dc:identifier>pmid:39565328</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae741</dc:identifier>
</item>
<item>
<title>Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565324/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>Non-bacterial thrombotic endocarditis (NBTE), formerly recognized as marantic endocarditis, represents a rare cardiovascular pathology intricately linked with hypercoagulable states, notably malignancy and autoimmune disorders. Characterized by the development of sterile vegetations comprised of fibrin and platelets on cardiac valves, NBTE poses a diagnostic challenge due to its resemblance to infective endocarditis. Therapeutic endeavours primarily revolve around addressing the underlying...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae788. doi: 10.1093/eurheartj/ehae788. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Non-bacterial thrombotic endocarditis (NBTE), formerly recognized as marantic endocarditis, represents a rare cardiovascular pathology intricately linked with hypercoagulable states, notably malignancy and autoimmune disorders. Characterized by the development of sterile vegetations comprised of fibrin and platelets on cardiac valves, NBTE poses a diagnostic challenge due to its resemblance to infective endocarditis. Therapeutic endeavours primarily revolve around addressing the underlying aetiology and instituting anticoagulant regimens to forestall embolic events, with surgical intervention seldom warranted. Non-bacterial thrombotic endocarditis frequently coexists with malignancies and autoimmune conditions, such as lupus and antiphospholipid antibody syndrome, and, more recently, has been associated with COVID-19. Its pathogenesis is underpinned by a complex interplay of endothelial dysfunction, hypercoagulability, hypoxia, and immune complex deposition. Clinical manifestations typically manifest as embolic phenomena, particularly cerebrovascular accidents, bearing substantial mortality rates. Diagnosis necessitates a high index of suspicion and meticulous exclusion of infective endocarditis, often facilitated by advanced cardiac imaging modalities. Anticoagulation, typically employing low molecular weight heparin or warfarin, constitutes the cornerstone of pharmacological intervention. Surgical recourse may be warranted in instances of refractory heart failure or recurrent embolic events. Given its multifaceted nature, the management of NBTE mandates a multidisciplinary approach, with prognosis contingent upon individual clinical intricacies. Future endeavours should prioritize further research to refine therapeutic strategies and enhance patient outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565324/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565324</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae788>10.1093/eurheartj/ehae788</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565324</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Omair Ahmed</dc:creator>
<dc:creator>Nicholas E King</dc:creator>
<dc:creator>Muhammad Ahmad Qureshi</dc:creator>
<dc:creator>Abira Afzal Choudhry</dc:creator>
<dc:creator>Muhammad Osama</dc:creator>
<dc:creator>Carl Zehner</dc:creator>
<dc:creator>Abdelrahman Ali</dc:creator>
<dc:creator>Ihab R Hamzeh</dc:creator>
<dc:creator>Nicolas L Palaskas</dc:creator>
<dc:creator>Kara A Thompson</dc:creator>
<dc:creator>Efstratios Koutroumpakis</dc:creator>
<dc:creator>Anita Deswal</dc:creator>
<dc:creator>Syed Wamique Yusuf</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal</dc:title>
<dc:identifier>pmid:39565324</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae788</dc:identifier>
</item>
<item>
<title>In memoriam: George L. Bakris, MD, 1952-2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565322/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae779. doi: 10.1093/eurheartj/ehae779. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565322/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565322</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae779>10.1093/eurheartj/ehae779</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565322</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew R Weir</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>In memoriam: George L. Bakris, MD, 1952-2024</dc:title>
<dc:identifier>pmid:39565322</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae779</dc:identifier>
</item>
<item>
<title>Erythritol and xylitol and cardiovascular disease risk: a growing concern</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565321/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae729. doi: 10.1093/eurheartj/ehae729. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565321/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565321</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae729>10.1093/eurheartj/ehae729</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565321</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marco Witkowski</dc:creator>
<dc:creator>Stanley L Hazen</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Erythritol and xylitol and cardiovascular disease risk: a growing concern</dc:title>
<dc:identifier>pmid:39565321</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae729</dc:identifier>
</item>
<item>
<title>Elevated serum xylitol levels and cardiovascular risk: an active component or an innocent bystander?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565320/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae731. doi: 10.1093/eurheartj/ehae731. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565320/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565320</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae731>10.1093/eurheartj/ehae731</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565320</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mario Bonomini</dc:creator>
<dc:creator>Valentina Masola</dc:creator>
<dc:creator>Edoardo Gronda</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Elevated serum xylitol levels and cardiovascular risk: an active component or an innocent bystander?</dc:title>
<dc:identifier>pmid:39565320</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae731</dc:identifier>
</item>
<item>
<title>Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565305/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae781. doi: 10.1093/eurheartj/ehae781. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565305/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565305</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae781>10.1093/eurheartj/ehae781</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565305</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gurleen Kaur</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Baris Gencer</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Norman E Lepor</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Elmer Stout</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Beat Knusel</dc:creator>
<dc:creator>Jeong-Gun Park</dc:creator>
<dc:creator>Huei Wang</dc:creator>
<dc:creator>You Wu</dc:creator>
<dc:creator>Helina Kassahun</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study</dc:title>
<dc:identifier>pmid:39565305</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae781</dc:identifier>
</item>
<item>
<title>A European network to develop virtual twin technology for personalized stroke management in atrial fibrillation: the TARGET consortium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae673. doi: 10.1093/eurheartj/ehae673. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565293</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae673>10.1093/eurheartj/ehae673</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565293</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sandra Ortega-Martorell</dc:creator>
<dc:creator>Ivan Olier</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>TARGET consortium</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A European network to develop virtual twin technology for personalized stroke management in atrial fibrillation: the TARGET consortium</dc:title>
<dc:identifier>pmid:39565293</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae673</dc:identifier>
</item>
<item>
<title>Happy birthday, Dr Braunwald!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae725. doi: 10.1093/eurheartj/ehae725. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565290</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae725>10.1093/eurheartj/ehae725</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565290</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Happy birthday, Dr Braunwald!</dc:title>
<dc:identifier>pmid:39565290</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae725</dc:identifier>
</item>
<item>
<title>Meet the team: editors Sean van Diepen, Kapka Miteva, Antoine Bondue, and Konstantinos Stellos</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39565281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 20:ehae712. doi: 10.1093/eurheartj/ehae712. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39565281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39565281</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae712>10.1093/eurheartj/ehae712</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39565281</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Meet the team: editors Sean van Diepen, Kapka Miteva, Antoine Bondue, and Konstantinos Stellos</dc:title>
<dc:identifier>pmid:39565281</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae712</dc:identifier>
</item>
<item>
<title>Charting the future of cardiology with large language model artificial intelligence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39562750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 19. doi: 10.1038/s41569-024-01105-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39562750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39562750</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01105-y>10.1038/s41569-024-01105-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39562750</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ramsey M Wehbe</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Charting the future of cardiology with large language model artificial intelligence</dc:title>
<dc:identifier>pmid:39562750</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01105-y</dc:identifier>
</item>
<item>
<title>Glia-like taste cells mediate an intercellular mode of peripheral sweet adaptation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39561773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>The sense of taste generally shows diminishing sensitivity to prolonged sweet stimuli, referred to as sweet adaptation. Yet, its mechanistic landscape remains incomplete. Here, we report that glia-like type I cells provide a distinct mode of sweet adaptation via intercellular crosstalk with chemosensory type II cells. Using the microfluidic-based intravital tongue imaging system, we found that sweet adaptation is facilitated along the synaptic transduction from type II cells to gustatory...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 9:S0092-8674(24)01258-3. doi: 10.1016/j.cell.2024.10.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The sense of taste generally shows diminishing sensitivity to prolonged sweet stimuli, referred to as sweet adaptation. Yet, its mechanistic landscape remains incomplete. Here, we report that glia-like type I cells provide a distinct mode of sweet adaptation via intercellular crosstalk with chemosensory type II cells. Using the microfluidic-based intravital tongue imaging system, we found that sweet adaptation is facilitated along the synaptic transduction from type II cells to gustatory afferent nerves, while type I cells display temporally delayed and prolonged activities. We identified that type I cells receive purinergic input from adjacent type II cells via P2RY2 and provide inhibitory feedback to the synaptic transduction of sweet taste. Aligning with our cellular-level findings, purinergic activation of type I cells attenuated sweet licking behavior, and P2RY2 knockout mice showed decelerated adaptation behavior. Our study highlights a veiled intercellular mode of sweet adaptation, potentially contributing to the efficient encoding of prolonged sweetness.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39561773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39561773</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.041>10.1016/j.cell.2024.10.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39561773</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gha Yeon Park</dc:creator>
<dc:creator>Geehyun Lee</dc:creator>
<dc:creator>Jongmin Yoon</dc:creator>
<dc:creator>Jisoo Han</dc:creator>
<dc:creator>Pyonggang Choi</dc:creator>
<dc:creator>Minjae Kim</dc:creator>
<dc:creator>Sungho Lee</dc:creator>
<dc:creator>Chaeri Park</dc:creator>
<dc:creator>Zhaofa Wu</dc:creator>
<dc:creator>Yulong Li</dc:creator>
<dc:creator>Myunghwan Choi</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Glia-like taste cells mediate an intercellular mode of peripheral sweet adaptation</dc:title>
<dc:identifier>pmid:39561773</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.041</dc:identifier>
</item>
<item>
<title>STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39560672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 19:ehae773. doi: 10.1093/eurheartj/ehae773. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39560672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39560672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae773>10.1093/eurheartj/ehae773</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39560672</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention</dc:title>
<dc:identifier>pmid:39560672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae773</dc:identifier>
</item>
<item>
<title>Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39560670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 19:ehae797. doi: 10.1093/eurheartj/ehae797. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39560670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39560670</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae797>10.1093/eurheartj/ehae797</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39560670</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dominik Linz</dc:creator>
<dc:creator>Sevasti-Maria Chaldoupi</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden</dc:title>
<dc:identifier>pmid:39560670</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae797</dc:identifier>
</item>
<item>
<title>First past the post: research on endurance exercise wins the Desmond Julian Award</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39560667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 19:ehae750. doi: 10.1093/eurheartj/ehae750. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39560667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39560667</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae750>10.1093/eurheartj/ehae750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39560667</guid>
<pubDate>Tue, 19 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-11-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>First past the post: research on endurance exercise wins the Desmond Julian Award</dc:title>
<dc:identifier>pmid:39560667</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae750</dc:identifier>
</item>
<item>
<title>Cholesterol crystals in the pathogenesis of atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39558130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>The presence of cholesterol crystals (CCs) in tissues was first described more than 100 years ago. CCs have a pathogenic role in various cardiovascular diseases, including myocardial infarction, aortic aneurysm and, most prominently, atherosclerosis. Although the underlying mechanisms and signalling pathways involved in CC formation are incompletely understood, numerous studies have highlighted the existence of CCs at various stages of atheroma progression. In this Review, we summarize the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 18. doi: 10.1038/s41569-024-01100-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The presence of cholesterol crystals (CCs) in tissues was first described more than 100 years ago. CCs have a pathogenic role in various cardiovascular diseases, including myocardial infarction, aortic aneurysm and, most prominently, atherosclerosis. Although the underlying mechanisms and signalling pathways involved in CC formation are incompletely understood, numerous studies have highlighted the existence of CCs at various stages of atheroma progression. In this Review, we summarize the mechanisms underlying CC formation and the role of CCs in cardiovascular disease. In particular, we explore the established links between lipid metabolism across various cell types and the formation of CCs, with a focus on CC occurrence in the vasculature. We also discuss CC-induced inflammation as one of the pathogenic features of CCs in the atheroma. Finally, we summarize the therapeutic strategies aimed at reducing CC-mediated atherosclerotic burden, including approaches to inhibit CC formation in the vasculature or to mitigate the inflammatory response triggered by CCs. Addressing CC formation might emerge as a crucial component in our broader efforts to combat cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39558130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39558130</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01100-3>10.1038/s41569-024-01100-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39558130</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yvonne Baumer</dc:creator>
<dc:creator>Jason Irei</dc:creator>
<dc:creator>William A Boisvert</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cholesterol crystals in the pathogenesis of atherosclerosis</dc:title>
<dc:identifier>pmid:39558130</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01100-3</dc:identifier>
</item>
<item>
<title>Semaglutide Eligibility Across All Current Indications for US Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 18:e244657. doi: 10.1001/jamacardio.2024.4657. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39556764</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11574724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">PMC11574724</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4657>10.1001/jamacardio.2024.4657</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556764</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ivy Shi</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Issa J Dahabreh</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Semaglutide Eligibility Across All Current Indications for US Adults</dc:title>
<dc:identifier>pmid:39556764</dc:identifier>
<dc:identifier>pmc:PMC11574724</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4657</dc:identifier>
</item>
<item>
<title>Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39556714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241120215120&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance and well-being; and reduced symptoms and medication burden in patients with HFpEF and obesity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072679. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical endpoints, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden in these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 731 patients in class II-IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m<sup>2</sup> were randomized(double-blind) to tirzepatide(titrated up to 15mg subcutaneously weekly)(n=364) or placebo(n=367), added to background therapy for a median of 104 weeks (Q1=66, Q3=126 weeks).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">PRIMARY ENDPOINTS: tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score(KCCQ-CSS). The current expanded analysis included sensitivity analyses of the primary endpoints, 6-minute walk distance(6MWD), EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health(PGIS), NYHA class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in KCCQ-CSS and 6MWD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients were aged 65.2±10.7, 53.8%(n=393) were female; BMI 38.2±6.7kg/m<sup>2</sup>, KCCQ-CSS 53.5±18.5, 6MWD 302.8±81.7meters, and 53%(n=388) had a worsening heart failure event in the prior 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time-to-first-event (hazard ratios 0.41-0.67). At 52 weeks, tirzepatide increased KCCQ-CSS 6.9 points (95%CI, 3.3, 10.6, P&lt;0.001), 6MWD 18.3 meters (95%CI, 9.9, 26.7, P&lt;0.001) and EQ-5D-5L 0.06 (95%CI, 0.03, 0.09, P&lt;0.001). The tirzepatide group shifted to a more favorable PGIS (proportional odds ratio 1.99 (95%CI, 1.44, 2.76) and NYHA class (proportional odds ratio 2.26 (95%CI, 1.54, 3.31), both P&lt;0.001 and required less heart failure medications (P=0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance and well-being; and reduced symptoms and medication burden in patients with HFpEF and obesity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39556714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241120215120&v=2.18.0.post9+e462414">39556714</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072679>10.1161/CIRCULATIONAHA.124.072679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39556714</guid>
<pubDate>Mon, 18 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Christopher M Kramer</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Yang Ou</dc:creator>
<dc:creator>Govinda J Weerakkody</dc:creator>
<dc:creator>Karla C Hurt</dc:creator>
<dc:creator>Chisom Kanu</dc:creator>
<dc:creator>Masahiro Murakami</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>SUMMIT Trial Study Group</dc:creator>
<dc:date>2024-11-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity</dc:title>
<dc:identifier>pmid:39556714</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072679</dc:identifier>
</item>





























</channel>
</rss>